Clinical Report: Examining 1115 Waiver Assessments for Medicaid Funding to IMD
Background
Medicaid plays a crucial role in funding treatment for adults with substance use disorders (SUDs), covering a significant portion of this population. Historically, federal law has restricted Medicaid payments for inpatient care in IMDs, which has limited access to necessary services. The introduction of SUD IMD waivers aimed to address these barriers and enhance treatment access.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
As of April 2026, 38 states and D.C. have adopted SUD IMD waivers for Medicaid funding.
Six states have completed summative evaluations.
Evaluation methods varied across states.
Challenges identified include workforce shortages and administrative barriers.
Most states reported decreases in SUD-related emergency department use.
Clinical Implications
Healthcare providers should be aware of the evolving landscape of Medicaid funding for SUD treatment, particularly regarding ongoing challenges such as workforce shortages and administrative barriers.
Conclusion
The evaluations of SUD IMD waivers indicate various challenges and outcomes, necessitating careful consideration of the systemic issues involved.
The judgment stemmed from controlled-substance prescriptions issued after William C. Gardner, DDS, no longer held the state licensure required for federal prescribing authority.
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
